Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00259766
Status:
COMPLETED
Last Update Posted:
2011-01-24
First Post:
2005-11-25
Brief Title:
SHARE - Symbicort and Health Economics in a Real Life Evaluation
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Symbicort and Health Economics in a Real Life Evaluation - SHARE - A Randomised Open-Label Parallel-Group Multicentre Study to Assess the Asthma-Related Health-Care Costs in Ordinary Clinical Practice During 12 Months
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare health-related costs and asthma control in ordinary clinical practice during 12 months for Symbicort given as a low maintenance dose plus as needed compared to a free combination of Pulmicortâ and Oxis plus Bricanyl as needed and Symbicort fixed dosing plus Bricanyl as needed in asthmatic patients not adequately controlled on inhaled glucocorticosteroids alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SHARE | None | None | None |